Literature DB >> 14976212

Bacterial penetration of bladder epithelium through lipid rafts.

Matthew J Duncan1, Guojie Li, Jeoung-Sook Shin, Johnny L Carson, Soman N Abraham.   

Abstract

Type 1 fimbriated Escherichia coli represents the most common human uropathogen, owing much of its virulence to invasion of the uroepithelium, which is highly impermeable due to the preponderance of uroplakins and highly ordered lipid components. We sought to elucidate the molecular basis for E. coli invasion of the bladder epithelium by employing human 5637 bladder epithelial cells, and we found the following: (i) intracellular E. coli associated with caveolae and lipid raft components; (ii) RNA(i) reduction of caveolin-1 expression inhibited bacterial invasion; (iii) a signaling molecule required for E. coli invasion was located in lipid rafts and physically associated with caveolin-1; (iv) bacterial invasion was inhibited by lipid raft disrupting/usurping agents. In the mouse bladder, the E. coli type 1 fimbrial receptor, uroplakin Ia, was located in lipid rafts, and lipid raft disruptors inhibited E. coli invasion. Cumulatively, E. coli uroepithelial invasion occurs through lipid rafts, which, paradoxically, contribute to bladder impermeability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976212     DOI: 10.1074/jbc.M400769200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression.

Authors:  Eyal Amiel; Rustin R Lovewell; George A O'Toole; Deborah A Hogan; Brent Berwin
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

Review 2.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

3.  Androgens Enhance Male Urinary Tract Infection Severity in a New Model.

Authors:  Patrick D Olson; Keith A Hruska; David A Hunstad
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

Review 4.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

5.  Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.

Authors:  Indira U Mysorekar; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-12       Impact factor: 11.205

6.  Characteristics of the phagocytic cup induced by uropathogenic Escherichia coli.

Authors:  Huaibin Wang; Feng-Xia Liang; Xiang-Peng Kong
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

Review 7.  TLR-mediated immune responses in the urinary tract.

Authors:  Jeongmin Song; Soman N Abraham
Journal:  Curr Opin Microbiol       Date:  2008-02-01       Impact factor: 7.934

8.  Spatiotemporal expression of UPK3B and its promoter activity during embryogenesis and spermatogenesis.

Authors:  Sei Kuriyama; Yuutaro Tamiya; Masamitsu Tanaka
Journal:  Histochem Cell Biol       Date:  2016-08-31       Impact factor: 4.304

9.  Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding.

Authors:  Swaine L Chen; Chia S Hung; Jerome S Pinkner; Jennifer N Walker; Corinne K Cusumano; Zhaoli Li; Julie Bouckaert; Jeffrey I Gordon; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-16       Impact factor: 11.205

10.  Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis.

Authors:  Gregory G Anderson; Carlos C Goller; Sheryl Justice; Scott J Hultgren; Patrick C Seed
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.